September 13, 2016

Heat Biologics to Present at Two Upcoming Investor Conferences

DURHAM, N.C., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced that the company is scheduled to present at the following investor conferences:

2016 Aegis Growth Conference

Date: Wednesday, September 21, 2016
Time: 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time)
Location: Encore at Wynn Las Vegas
Webcast: http://ir.heatbio.com/events-presentations. The webcast will be archived on the company's website for a period of three months.

OktoberINVESTfest 5th Annual Investors Conference

Date: Wednesday, September 28, 2016
Time: 1:15 p.m. Eastern Time
Location: The New York Academy of Sciences

About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer. Heat's highly specific T cell-stimulating platform technologies, *ImPACT* and *ComPACT*, form the basis of its product candidates. These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ "killer" T cells (one of the human immune system's most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients' immune response. Currently, Heat is conducting a Phase 2 trial with its HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC) and a Phase 1b trial with its HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC). For more information, please visit www.heatbio.com.

CONTACT:
For Investor Inquiries:
David Waldman
919-240-7133
Investorrelations@heatbio.com

For Media Inquiries:
Deanne Eagle
Planet Communications

917-837-5866
deanne@planetcommunications.nyc

Source: Heat Biologics